Rheumatologists on the Move

Dr. Wilhelm says, “I am certainly excited to add to the interesting portfolio of drugs in development for oncology and autoimmune diseases,” in his new position being in charge of clinical development activities.

One of those activities involves, in collaboration with UCB, SA, a biopharma company based in Belgium with offices in 40 countries, Phase III development of epratuzumab, an investigational medicine for the treatment of moderate and severe systemic lupus erythematosus. There were seven presentations on SLE and investigational studies of epratuzumab given at the 2014 ACR/ARHP Annual Meeting.

Ann-Marie Lindstrom is an independent writer and editor based in the Tucson, Ariz., area.